Xpovio mulligan in endometrial cancer misses primary endpoint while Karyopharm presses on in myelofibrosis
Karyopharm’s Xpovio (selinexor) failed to meet the primary progression‑free survival endpoint in its Phase 3 XPORT‑EC‑042 trial in TP53 wild‑type advanced or recurrent endometrial cancer, though a numerical trend favoring selinexor was seen (median PFS 12.75 vs 7.43 months, HR 0.76, p=0.0791). The company’s maintenance‑therapy bid in endometrial cancer follows an earlier FDA rejection of a broader Xpovio label expansion, which prompted a redesign around the TP53 wild‑type subgroup. In myelofibrosis, selinexor plus ruxolitinib met its first co‑primary spleen‑volume endpoint (50% SVR35 vs 28%), but missed the symptom‑score endpoint; Karyopharm nonetheless plans an FDA discussion on an sNDA based on spleen‑response and survival signals, even as Xpovio’s endometrial path now looks uncertain.
Sources:
Karyopharm's pipeline of investigational medicines
Karyopharm myeloma drug yields mixed data in ...
Xpovio Has 'Potential to Transform' Treatment of Advanced ...
Can mixed results gain an expansion for Karyopharm's Expovio?
Karyopharm Reports Mixed Study Result, Raises $30 Million
Karyopharm Completes Phase 3 Endometrial Cancer Enrollment
Karyopharm’s Phase III myelofibrosis trial delivers mixed results
FDA says no, thank you to Xpovio's cancer expansion bid, prompting Karyopharm to run new study
Maintenance therapy with Xpovio may extend PFS in some ...
Karyopharm plummets as Xpovio fails in phase 3 trial for endometrial cancer